PRECLINICAL STUDY
Endothelial Nitric Oxide Synthase Overexpression Provides a Functionally Relevant Angiogenic Switch in Hibernating Pig Myocardium
Christian Kupatt, MD*,*,
Rabea Hinkel, DVM*,
Marie-Luise von Brühl, DVM*,
Tilmann Pohl, MD*,
Jan Horstkotte, MD*,
Philip Raake, MD*,
Chiraz El Aouni, PhD*,
Eckehard Thein, DVM ,
Stefanie Dimmeler, PhD ,
Olivier Feron, PhD and
Peter Boekstegers, MD*
* Internal Medicine I, Klinikum Grosshadern
Institute of Surgical Research, Ludwig-Maximilians-University of Munich, Munich, Germany
Molecular Cardiology, Department of Medicine IV, University of Frankfurt, Frankfurt, Germany
Unit of Experimental Pharmacology, Catholique University of Leuven, Brussels, Belgium
Manuscript received June 7, 2006;
revised manuscript received October 19, 2006,
accepted November 27, 2006.
* Reprint requests and correspondence: Dr. Christian Kupatt, Internal Medicine I, Klinikum Großhadern, Marchioninistr. 15, 81377 Munich, Germany. (Email: christian.kupatt{at}med.uni-muenchen.de).
Objectives: We investigated whether retroinfusion of liposomal endothelial nitric oxide synthase (eNOS) S1177D complementary deoxyribonucleic acid (cDNA) would affect neovascularization and function of the ischemic myocardium.
Background: Recently, we demonstrated the feasibility of liposomal eNOS cDNA transfection via retroinfusion in a model of acute myocardial ischemia/reperfusion. In the present study, we used this approach to target a phosphomimetic eNOS construct (eNOS S1177D) into chronic ischemic myocardium in a pig model of hibernation.
Methods: Pigs (n = 6/group) were subjected to percutaneous implantation of a reduction stent graft into the left anterior descending artery (LAD), inducing total occlusion within 28 days. At day 28, retroinfusion of saline solution containing liposomal green fluorescent protein or eNOS S1177D cDNA (1.5 mg/animal, 2 x 10 min) was performed. Furthermore, L-nitroarginine-methylester (L-NAME) was applied orally from day 28, where indicated. At day 28 and day 49, fluorescent microspheres were injected into the left atrium for perfusion analysis. Regional functional reserve (at atrial pacing 140/min) was assessed at day 49 by subendocardial segment shortening (SES) (sonomicrometry, percent of ramus circumflexus region).
Results: The eNOS S1177D overexpression increased endothelial cell proliferation as well as capillary and collateral growth at day 49. Concomitantly, eNOS S1177D overexpression enhanced regional myocardial perfusion from 62 ± 4% (control) to 77 ± 3% of circumflex coronary arteryperfused myocardium, unless L-NAME was co-applied (69 ± 5%). Similarly, eNOS S1177D cDNA improved functional reserve of the LAD (33 ± 5% vs. 7 ± 3% of circumflex coronary arteryperfused myocardium), except for L-NAME coapplication (13 ± 6%).
Conclusions: Retroinfusion of eNOS S1177D cDNA induces neovascularization via endothelial cell proliferation and collateral growth. The resulting gain of perfusion enables an improved functional reserve of the hibernating myocardium.
|
Abbreviations and Acronyms
| | ANOVA = analysis of variance | | cDNA = complementary deoxyribonucleic acid | | cGMP = cyclic guanosine monophosphate | | eGFP = endothelial green fluorescent protein | | eNOS = endothelial nitric oxide synthase | | IGF = insulin-like growth factor | | LAD = left anterior descending artery | | L-NAME = L-nitroarginine-methylester | | RCx = ramus circumflexus | | SES = subendocardial segment shortening | | VEGF = vascular endothelial growth factor |
|
This article has been cited by other articles:

|
 |

|
 |
 
M. S. Penn and A. A. Mangi
Genetic Enhancement of Stem Cell Engraftment, Survival, and Efficacy
Circ. Res.,
June 20, 2008;
102(12):
1471 - 1482.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Viita, J. Markkanen, E. Eriksson, M. Nurminen, K. Kinnunen, M. Babu, T. Heikura, S. Turpeinen, S. Laidinen, T. Takalo, et al.
15-Lipoxygenase-1 Prevents Vascular Endothelial Growth Factor A- and Placental Growth Factor-Induced Angiogenic Effects in Rabbit Skeletal Muscles via Reduction in Growth Factor mRNA Levels, NO Bioactivity, and Downregulation of VEGF Receptor 2 Expression
Circ. Res.,
February 1, 2008;
102(2):
177 - 184.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|